ER Mardis
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
32
Citations
216
Est. group size
—
Recurring co-author estimate
Active years
37
Publishing since 1990
This researcher uses genome sequencing and other large-scale molecular profiling methods to study cancer, especially breast cancer, examining how tumor genetics change over time and how these changes relate to treatment response and drug resistance. Much of the work involves large clinical trial cohorts, analyzing tumor DNA, immune cell patterns, and gene mutations to understand why some cancers respond to therapies like chemotherapy, targeted antibody drugs, or immune checkpoint blockade while others do not. The research also touches on genetic factors in other conditions, such as primary ovarian insufficiency.
Publication output was moderate from 2017–2019, dropped to near zero between 2020 and 2024, and shows a recent uptick with new entries in 2025 and 2026, though the 5-year average remains low.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Abstract PD3-09: Molecular characterization of resistance to antibody drug conjugates in metastatic breast cancer: a prospective analysis from the AURORA US Network
Clinical Cancer Research · 2026
- Causal and Candidate Gene Variants in a Large Cohort of Women with Primary Ovarian Insufficiency
medRxiv · 2021
- Association of Tumor Microenvironment T-Cell Repertoire and Mutational Load With Clinical Outcome After Sequential Checkpoint Blockade in Melanoma
immuneACCESS · 2019
- Abstract P2-05-01: Whole genome sequencing reveals enrichment of mutations in mucin gene family in breast cancer diagnosed during pregnancy
Cancer Research · 2018
- Abstract GS2-01: Discovery and characterization of an estrogen bound LncRNA in late-Stage breast cancer
Cancer Research · 2018
- Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis
immuneACCESS · 2018
- Abstract P1-06-06: Evidence for tumor heterogeneity and clonal evolution during invasive progression of breast cancer
Cancer Research · 2017
- Abstract P1-05-30: Genomic and microenvironmental intra-tumor heterogeneity in DCIS
Cancer Research · 2017
- Abstract P1-07-11: Tumor genomic profiling of triple negative breast cancer during neoadjuvant chemotherapy: Results from a prospective trial of carboplatin and docetaxel
Cancer Research · 2017
- Abstract S3-05: Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer
Cancer Research · 2017
- Abstract PD6-02: The genomics of response to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer – Results from the ACOSOG Z1041 (Alliance) trial
Cancer Research · 2016
- Abstract P6-05-03: Genomic diversity of ductal carcinoma in situ (DCIS) as a driver of invasion and metastasis
Cancer Research · 2016
- Cancer Research×8
- immuneACCESS×2
- medRxiv×1
- Clinical Chemistry×1
- OncoImmunology×1
- A.V. Parwani
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Daniel G. Stover
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Nawal Kassem
Biochemistry, Genetics and Molecular Biology · Indiana University
- David Tallman
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Ashiq Masood
Biochemistry, Genetics and Molecular Biology · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile